Cormorant Asset Management, LP Atreca, Inc. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $750,271 - $1.56 Million	-480,943 Reduced 60.12%	319,057 $571,000
Q1 2022 May 16, 2022	BUY	$1.61 - $5.2 $847,665 - $2.74 Million	526,500 Added 192.5%	800,000 $2.54 Million
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $156,400 - $276,000	-20,000 Reduced 6.81%	273,500 $2.33 Million
Q3 2020 Nov 16, 2020	SELL	$12.67 - $23.19 $352,504 - $645,192	-27,822 Reduced 8.66%	293,500 $4.1 Million
Q2 2020 Aug 14, 2020	SELL	$12.52 - $23.45 $60,308 - $112,958	-4,817 Reduced 1.48%	321,322 $6.84 Million
Q1 2020 May 15, 2020	SELL	$11.4 - $27.28 $22 - $54	-2 Reduced -0.0%	326,139 $5.4 Million
Q4 2019 Feb 14, 2020	SELL	$9.68 - $18.67 $774,409 - $1.49 Million	-80,001 Reduced 19.7%	326,141 $5.05 Million
Q3 2019 Nov 14, 2019	SELL	$10.42 - $22.04 $404,296 - $855,152	-38,800 Reduced 8.72%	406,142 $4.97 Million
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $7.6 Million - $8.38 Million	444,942 New	444,942 $8.38 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.